31
Participants
Start Date
June 27, 2018
Primary Completion Date
February 14, 2023
Study Completion Date
February 14, 2023
Imlifidase
This is a five year, long-term follow up, observational study. The study will primarily determine the time of graft survival in subjects who have received imlifidase prior to kidney transplantation. Subjects who have participated, or are currently participating, in the imlifidase kidney transplantation studies (called feeder studies) 13-HMedIdeS-02, 13-HMedIdeS-03, 14-HMedIdeS- 04 and 15-HMedIdeS-06 will be included. The subjects will attend 4 follow up visits, 1, 2, 3 and 5 years after imlifidase administration.
New York University School of Medicine, New York
Karolinska University Hospital, Stockholm
The Johns Hopkins Hospital, Baltimore
Necker Hospital, Paris
Cedars-Sinai Medical Center, Los Angeles
Uppsala University Hospital, Uppsala
Lead Sponsor
Hansa Biopharma AB
INDUSTRY